TABLE 1.
Renal transplant–recipient characteristics stratified by cytomegalovirus (CMV) risk status and by immunosuppression protocols
| Moderate risk (n = 114, 65.1%) | High risk (n = 61, 34.9%) | Total (n = 173) | ||||
|---|---|---|---|---|---|---|
| Belatacept a (n = 74) | Tacrolimus (n = 39) | Belatacept (n = 41) | Tacrolimus (n = 19) | Belatacept (n = 115) | Tacrolimus (n = 58) | |
| Age at Tx | ||||||
| Mean (SD) | 52.1 (12.4) | 52.5 (12.5) | 52.2 (10.6) | 42.6 (12.5) | 52.1 (11.7) | 49.3 (13.2) |
| Median a [Min, Max] | 52.4 [23.8, 78.0] | 55.5 [29.4, 82.2] | 51.0 b [24.8, 70.2] | 43.5 b [25.4, 66.6] | 51.9 [23.8, 78.0] | 50.2 [25.4, 82.2] |
| Sex | ||||||
| Female | 32 (43.2%) | 22 (56.4%) | 10 (24.4%) | 7 (36.8%) | 42 (36.5%) | 29 (50.0%) |
| Male | 42 (56.8%) | 17 (43.6%) | 31 (75.6%) | 12 (63.2%) | 73 (63.5%) | 29 (50.0%) |
| Race | ||||||
| Black | 45 (60.8%) | 24 (61.5%) | 19 (46.3%) | 12 (63.2%) | 64 (55.7%) | 36 (62.1%) |
| Non‐Black | 29 (39.2%) | 15 (38.5%) | 22 (53.7%) | 7 (36.8%) | 51 (44.3%) | 22 (37.9%) |
| Donor type | ||||||
| Deceased | 53 (71.6%) | 25 (64.1%) | 29 (70.7%) | 12 (63.2%) | 82 (71.3%) | 37 (63.8%) |
| Living | 21 (28.4%) | 14 (35.9%) | 12 (29.3%) | 7 (36.8%) | 33 (28.7%) | 21 (36.2%) |
Note: All patients were transplanted at Emory Transplant Center between 2010 and 2017 and were considered to have entered a viremia states within 1 year after transplantation.
a
Median [minimum, maximum].
b
Belatacept‐treated recipients within the high‐risk group had a significantly higher medium age at transplant than did the tacrolimus‐treated recipients (p < .05).